Question · Q3 2025
Nick Larissa asked about the factors contributing to the significant increase in ARCALYST prescribers this quarter, Kiniksa's strategy for sustaining this uptake, and the estimated proportion of recurrent pericarditis patients seen by the current 3,800+ prescribers.
Answer
Ross Moat (Chief Corporate and Commercial Officer, Kiniksa Pharmaceuticals) attributed the record increase of over 350 new prescribers to increased confidence, awareness, and the recent ACC guidance. He detailed Kiniksa's targeted approach, including AI and digital innovation to guide field teams, and broad digital marketing efforts. He also noted that while the exact proportion of patients seen by these prescribers is hard to quantify, there's a significant opportunity due to high rates of underdiagnosis and misdiagnosis (average 2.7 misdiagnoses per patient).